The Current Multidrug Resistant Escherichia Coli Pandemic: Exploring Novel Therapies Against The Predominant Culprit E. Coli ST131.
Funder
National Health and Medical Research Council
Funding Amount
$512,223.00
Summary
Escherichia coli ST131 is a pandemic superbug. Like MRSA, E. coli ST131 infections are resistant to multiple antibiotics and can become life threatening. This study will show how adhesion can be the 'Achilles' heel' of this global pathogen and how blocking E. coli ST131 adhesion offers an alternative therapy for multidrug resistant human infections. As we are left with no effective antimicrobials to treat E. coli ST131 infections, this work will provide novel outcomes that are sorely needed.